Meshkatalsadat, M. H.; Shahsafi, M. A.; Parekh, Hansa, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1988, vol. 27, # 1-12, p. 195 - 196
Biochemical and pharmacological evaluation of 4-hydroxychromen-2-ones bearing polar C-3 substituents as anticoagulants
摘要:
The objective of this study was to investigate in vitro and in vivo anticoagulant activity of sixteen 4-hydroxycoumarin derivatives bearing polar C-3 scaffolds. The activity was evaluated by measuring prothrombin time. Enhanced anticoagulant activity in vitro was observed for all tested compounds. Upon successive administration of 0.5 mg/kg of body weight to adult Wistar rats, over a period of five days, four derivatives (2b, 4c, 5c and 9c) presented anticoagulant activity in vivo. The most active compound was 2b, with PT = 30.0 s. Low or non-toxic effects in vivo were determined based on the catalytic activity of liver enzymes and the concentration of bilirubin, iron and proteins. Metabolic pathways of the most active compounds in vivo were determined after GC/MS analysis of collected rat urine samples. The excretion occurs by glucuronidation of 7-hydroxy forms of tested derivatives. In vivo results were described using PLS-based CoMFA and CoMSIA 3D-QSAR studies, which showed CoMFA-SE (q(2) = 0.738) and CoMSIA-SEA (q(2) = 0.763) to be the statistically most relevant models. Furthermore, molecular docking and DFT mechanistic studies performed on the rat VKORC1 homology model revealed interactions between the 4-OH coumarin group in the form of phenolic anion and the Cys135 catalytic site in the transition state. (C) 2012 Elsevier Masson SAS. All rights reserved.
Syntheses of 2‐aminothiazolederivatives of 4‐hydroxy‐chromene‐2‐one 2c–10c are reported in this paper. These compounds 2c–10c were prepared from 3‐(2‐bromoacetyl)‐4‐hydroxy‐chromene‐2‐one 1 and corresponding thiourea derivatives 2b–10b using Hantzsch reaction. The structures of all compounds were confirmed by IR and 1H‐NMR spectroscopy and elemental analyses. The molecules 2c–10c were evaluated for in vitro
Anionic or cationic dendrimer antimicrobial or antiparasitic compositions
申请人:STARPHARMA LIMITED
公开号:US20030129158A1
公开(公告)日:2003-07-10
To inhibit, prophylactically or therapeutically, a bacterial, yeast, fungal, or parasitic agent in a patient, an effective amount of a dendrimer is administered to the patient, which dendrimer has a plurality of terminal groups, at least one of which has an anionic- or cationic-moiety covalently bonded or linked thereto. The anionic-containing moiety is not a disaccharide or oligosaccharide moiety, and, where the anionic-containing moiety is a neuraminic- or sialic acid-containing moiety, it is modified in the 4-position by substitution with an amino, amido, cyano, azido or guanido group, or is unsaturated.
An antiviral compound comprises a linear non-carbohydrate polymer having a plurality of side chain groups, wherein at least one of the side chain groups has an anionic-or cationic-containing moiety bonded or linked thereto.